BioSpace News Archive

Modular Medical, Inc., a medical device company focused on next generation insulin delivery technologies to widen the accessibility of insulin pumps to a greater share of people with type 1 and type 2 diabetes, announced that it has entered into definitive agreements for a private placement of $6.6 million of convertible promissory notes.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, announced its cash position as of March 31, 2021 and revenues for the first three months of 2021.

Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, reported consolidated financial results for the three months ended March 31, 2021.

CooperCompanies announced that its Board of Directors has elected Dr. Maria Rivas as an independent director, effective July 1, 2021.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today provides a business update and reports financial results for the quarter ended March 31, 2021.

CVS Health announced that COVID-19 vaccine appointments for adolescents ages 12 to 15 are now available for scheduling at more than 5,600 CVS Pharmacy locations nationwide, following Food and Drug Administration Emergency Use Authorization of the Pfizer-BioNTech vaccine for this age group.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced financial results for the first quarter ended March 31, 2021.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in the following upcoming investor conferences

Extendicare Inc. reported results for the three months ended March 31, 2021. Results are presented in Canadian dollars unless otherwise noted.